| Autor: |
Martin A; Syngulon, Seraing, Belgium., Bland MJ; Syngulon, Seraing, Belgium., Rodriguez-Villalobos H; Microbiology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium., Gala JL; Center for Applied Molecular Technologies (CTMA), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium., Gabant P; Syngulon, Seraing, Belgium. |
| Jazyk: |
angličtina |
| Zdroj: |
Microbial drug resistance (Larchmont, N.Y.) [Microb Drug Resist] 2023 May; Vol. 29 (5), pp. 165-174. Date of Electronic Publication: 2022 Jul 18. |
| DOI: |
10.1089/mdr.2021.0429 |
| Abstrakt: |
In this study, we assessed the potential of bacteriocins and their in vitro synergistic effects in combination with anti-tuberculosis drugs against Mycobacterium tuberculosis . We evaluated the in vitro activity of chemically synthesized bacteriocins in combination with rifampicin (RIF), ofloxacin, and moxifloxacin against the reference M. tuberculosis H37Rv and a clinical-resistant strain. We first screened the bacteriocin PARAGEN collection and found active bacteriocins. We then determined their minimal inhibitory concentration (MIC), minimal bactericidal concentration, and their fractional inhibitory index by the checkerboard microdilution assay. Remarkably, we identified four bacteriocins with interesting antimycobacterial activity alone and in combinations with RIF, ofloxacin, and moxifloxacin, with significant reduction of the MIC that showed impressive synergistic effects against the susceptible and resistant clinical strains. In conclusion, our preliminary results show promising bacteriocins candidate used in a synergistic combination with anti-tuberculosis drugs and emphasize the need for combined therapy as a new strategy to enhance the activity of existing drugs, which may confer very promising therapeutic benefits against M. tuberculosis . |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
